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Summary In a case-control study of second primary cancers in Moscow, there were 165 cases and 294
controls, matched for site of first primary, duration of follow-up since first primary and relapse history. Of the
cases, 18 were of acute, non-lymphocytic leukaemia (ANLL), with 39 matched controls. Risk of ANLL was
assessed with respect to chemotherapy for the first primary tumour. The chemotherapeutic agents investigated
were nitrogen mustard, cyclophosphamide, procarbazine, doxorubicin, bleomycin, vinblastine, vincristine,
prednisone and combinations. Increased risks were associated with use of nitrogen mustard (odds ratio = 9.94,
not significant), doxorubicin (odds ratio = 11.25, 0.1 > P> 0.05) and vincristine (odds ratio = 26.57, P<0.05).
Despite the small number of cases and potential confounding by other agents, these findings, together with
those of previous studies, suggest that some non-alkylating agents may predispose to second malignancies.
It is well-established that cancer chemotherapy with alky-
lating agents confers an increased risk of subsequent non-
lymphocytic leukaemia (Reimer et al., 1977; Henry-Amar,
1983; Kaldor et al., 1990a; 1990b). The increased risk has
been demonstrated in association with single agents and in
combination with other alkylating agents or non-alkylating
drugs (Kaldor et al., 1990a; 1990b). Evidence for or against
leukaemogenicity or carcinogenicity of non-alkylating cancer
chemotherapies, unconfounded by combination use with
alkylating agents is not available (International Agency for
Research on Cancer, 1987).
With respect to the effect of chemotherapies on risk of
solid second primary tumours, some studies have suggested
that certain combinations do increase risk (Henry-Amar,
1983), while others conclude that any increase in rates is
consistent with that expected from immunosuppression or
radiation exposure (Tucker et al., 1988).
In this paper we report on the effects of particular chemo-
therapeutic agents and combinations on risk of subsequent
acute non-lymphocytic leukaemia (ANLL) in a case-control
study of second primary cancers in Moscow.
Materials and methods
Cases were subjects with second primary cancers treated at
the All-Union Cancer Research Center, Moscow, between
1975 and 1990, and at the Cancer Institute, Saint-Petersburg,
between 1980 and 1990. All cases had their original primary
tumours treated at these institutes. Cases were defined by
having the following first primaries: Hodgkin's lymphoma,
non-Hodgkin's lymphoma, and cancers of the ovary, breast
and testis. For each case, between one and four controls were
selected, depending on availability, matched for age (within 1
year), sex, site of first primary cancer and duration of follow-
up since first primary cancer, so that for a case whose second
primary occurred 5 years after the first, the controls would
have 5 years follow-up in which they were known to be free
of second primary cancers. The criteria for selection of cases
and controls were adapted from the protocol of the IARC
International Study of Second Malignancies in Relation to
Cytotoxic Therapy (Kaldor et al., 1990a).
As mentioned above, for organisational reasons it was
necessary to recruit controls from hospital or clinic patients,
and this was likely to bias results towards a greater history of
therapy in controls, since controls in hospital were more
likely to be in relapse. To avoid this bias, cases and controls
were also matched for numbers of relapses, i.e. controls who
had a greater number of relapses than their cases were not
included. While this is arguably overmatching, the conserva-
tive bias which might result was considered less serious than
the near-certainty of control selection bias without this
device. It should be borne in mind that as a result of the
matching procedure, true differences between cases and cont-
rols are likely to be greater than those observed. This proce-
dure yielded 165 cases and 294 controls.
Table I shows the sex and age distribution of subjects in
the study at the first diagnosis. There were 20 male cases and
43 male controls, and 145 female cases and 251 female
controls. The large number of female subjects reflects the
considerable number of breast cancer cases as first primaries.
Table II shows cases by first and second cancer sites. For
cases of ANLL and their controls, the following agents were
used to treat the first primary in a large enough proportion
for statistical analysis: cyclophosphamide, nitrogen mustard,
procarbazine, doxorubicin, bleomycin, vinblastine, vincristine
and prednisone. The conventional combination chemother-
apy of mechlorethamine, vinblastine, procarbazine and pred-
nisone (MOPP) was not widely used in this population but a
variation of this, with mechlorethamine invariably replaced
by cyclophosphamide and vinblastine occasionally replaced
by vincristine, was commonly used (this combination referred
to as COPP below).
Statistical analysis was by conditional logistic regression
(Breslow & Day, 1980), yielding odds ratio estimates of
relative risk and deviance chi-squared tests for effect. In most
cases, the effects of chemotherapies were assessed relative to
a baseline group of patients who received only radiotherapy
and/or surgery as treatment of their first primary tumour. As
is the case in previous studies, use of only a single
chemotherapeutic agent was too rare to completely rule out
potential confounding by other agents. As cases were scarce,
results reported here pertain to all ANLL second primaries,
but these were checked by repeating the analyses restricted to
those whose first primary was Hodgkin's disease, and similar
results were obtained.
Results
Table III shows the distributions of radiotherapy and chemo-
therapy for all cases and controls, showing an increased risk
associated with both therapies. Further, the odds ratio for
chemotherapy plus radiotherapy relative to radiotherapy
alone was 2.65, with 95% confidence interval (1.25,5.60).
Correspondence: D.G. Zaridze, Department of Epidemiology, All-
Union Cancer Research Center AMS-USSR, 24 Kashirskoye Shosse,
Moscow 115678, Russia.
Received 26 August 1991; and in revised form 28 August 1992.
Br. J. Cancer (1993), 67, 347-350 '." Macmillan Press Ltd., 1993348 D.G. ZARIDZE et al.
Table I Age and sex distributions of cases and controls
Age atfirst Cases Controls
diagnosis Males Females Males Females
15-19 0 0 0 3
20-24 0 6 0 13
25-29 0 5 1 10
30-34 1 2 2 4
35-39 3 6 11 13
40-44 3 14 6 22
45-49 3 27 4 39
50-54 1 26 3 54
55-59 3 19 3 35
60-64 1 19 2 25
65-69 0 11 4 22
70-74 4 7 5 10
75-79 1 2 2 1
80-84 0 1 0 0
Table IV(a) and (b) gives the corresponding data for ANLL
cases. No ANLL cases had chemotherapy and no radio-
therapy, so it was impossible to estimate the relative risk for
chemotherapy only. Consequently, only relative risks for
chemotherapy and radiotherapy adjusted for each other are
presented in Table IV(a). Chemotherapy in general conferred
an increased risk but this was not significant.
Table V shows odds ratios associated with histories of the'
chemotherapeutic agents listed above. A significant increase
in risk was observed in association with vincristine use, and
an almost significant increase in association with doxorubicin
use. Due to small numbers it was possible to assess quanti-
tative effects of numbers of cycles of chemotherapy only for
nitrogen mustard, cyclophosphamide, procarbazine, vincris-
tine, vinblastine and prednisone. Results are shown in Table
VI. It is clear that data were too sparse for a thorough
analysis of dose-response, although some evidence of a trend
was observed for procarbazine and vincristine.
Discussion
The implications of this study are at best hypothesis-forming.
Because of the large confidence intervals our generally nega-
tive findings with respect to cyclophosphamide are not incon-
sistent with positive or suggestive findings elsewhere (Kaldor
Table III Distributions ofall cases and controls by radiotherapy and
chemotherapy histories
Treatment history Cases Controls Off (95% CIb)
Neither 24 49 1.00
Radiotherapy only 28 55 1.15 (0.56,2.35)
Chemotherapy only 39 107 1.02 (0.52,1.99)
Both 74 83 2.47 (1.29,4.74)
'OR = odds ratio. bCI = confidence interval.
Table IV Distributions ofANLL cases and controls by radiotherapy
and chemotherapy histories
Treatment history Cases Controls ORa (95% CIb)
(a) All ANLL cases and their controls
No radiotherapy 1 11 1.00
Radiotherapy 17 28 7.45C (0.87,63.08)
No chemotherapy 1 6 1.00 -
Chemotherapy 17 33 3.35 (0.38,29.54)
(b) Only those subjects with a history of radiotherapy
Radiotherapy only 1 7 1.00
Both 16 21 4.48 (0.52,37.93)
'OR = odd ratios, chemotherapy adjusted for radiotherapy and vice
versa. bCI = confidence interval. C0.I >P>0.05.
et al., 1990a; 1990b; Haas et al., 1987). Sparse data and
consequently wide interval estimates are common in research
in this field, by nature of the relative rarity of second
primaries (Henry-Amar, 1983; Kaldor et al., 1990b; Haas et
al., 1987; De Gramont et al., 1986). Further, the matching
problems described above may have contributed to the nega-
tive findings. Our observed relative risk of 9.94 in association
with nitrogen mustard use is consisent with the findings of
Kaldor et al. (1990b) with respect to combination therapies
including mechlorethamine.
The present results indicate an increased risk associated
with vincristine use and a possible increased risk associated
with doxorubicin use. These are commonly used in combina-
tion with each other in these data, and vincristine is also
commonly used in combination with nitrogen mustard, so
the increased risks cannot be definitely attributed to one or
other of these agents. Due to the small numbers and the
potential confounding with other agents, these findings must
Table II Distribution of cases by first and second primary site
Secondprimary
cancer site
Breast
Lung
Oesophagus
Ovary
Stomach
Kidney
Uterus
Colon
Rectum
Connective tissue
Thyroid
Gall bladder
Bladder
Melanoma
Parotid gland
Tongue
Cervix uteri
Nasopharynx
ANLL
Prostate
Non-Hodgkin's
Larynx
Liver
Total
Hodgkin's
7
1
0
0
1 0
0 0
1
0
1
0
0
0
1
0
0
1
13
l
0
0
0
28
Breast
0
15
3
10
20
4
10
17
7
3
4
1
0
5
0
1
6
0
4
0
1
0
112
First primary cancer site
Non-Hodgkin's Ovary
1 5
0 1
0 0
0 0
0 2
1 0
0 1
2 1
0 2
1 0
0 0
0 0
1 0
0 0
0 0
0 0
0 0
0 0
0 0
2 0
0 1
0 0
1 0
9 13
Testis
0
0
0
0
0
1
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
3
Total
13
17
3
10
23
6
11
20
10
5
6
1
1 5
6
1 18
3
2
1
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await confirmation in other studies, but it should be noted
that indirect evidence from some previous studies at least
suggests that non-alkylating chemotherapies may also predis-
pose to second cancers. In persons treated for ovarian cancer,
Haas et al. (1987) found a relative risk of subsequent leu-
kaemia of 7.6 in association with cyclophosphamide and of
15.7 in association with any chemotherapy. In Kaldor et al.'s
Table V Distribution of cases and controls, odds ratios and 95%
confidenceintervals, relative topatientsreceivingradiotherapyonly, by
history ofvarious chemotherapeutic agents
Agent Cases Controls OR
a (95% CIb)
Radiotherapy only 2 8 1.00 -
(a) Alkylating agents
Nitrogen mustard 3 3 9.94 (0.61,160.10)
Cyclophosphamide 10 24 1.52 (0.25,8.98)
Any alkylating agents 12 28 3.03 (0.33,27.35)
(b) Other agents
Doxorubicin 5 1 11.25c (0.91,138.70)
Bleomycin 4 2 8.01 (0.75,85.23)
Procarbazine 9 24 1.37 (0.20,9.04)
Vincristine 10 4 26.57d (1.76,400.80)
Vinblastine 8 24 1.22 (0.21,7.11)
Prednisone 13 27 4.10 (0.30,55.28)
(c) Combination
Coppe 6 21 0.79 (0.11,5.44)
Any combination 12 29 1.49 (0.26,8.45)
aOR = odds ratio. bCI = confidence interval. c0.1 >P> 0.05;
dp<0.05. eCopp = combination ofcyclophosphamide, vincristine or
vinblastine, procarbazine and prednisone.
Table VII Distributions ofall solid tumour secondprimary cases and
their controls by radiotherapy and chemotherapy histories
Treatment history Cases Controls OR' (95% Clb)
Neither 23 48 1.00
Radiotherapy only 27 47 1.24 (0.59,2.58)
Chemotherapy only 38 94 1.14 (0.57,2.24)
Both 57 61 2.35 (1.20,4.60)
'OR = odds ratio. bCI = confidence interval.
(1990b) case-control study of leukaemia after Hodgkin's
disease, 11 cases and 158 controls received radiotherapy only,
while nine cases and 12 controls received combination
chemotherapies which did not include alkylating agents, yield-
ing a naive odds ratio of 10.8. Further, doxorubicin has been
found to be carcinogenic in animal experiments (Interna-
tional Agency for Research on Cancer, 1987).
Future work in the present study includes the possible
assessment of risk of second primary cancers other than
leukaemias. Table VII shows the corresponding results to
Table III for all cancers except leukaemia and lymphoma.
There is certainly a suggestion that chemotherapy plays a
role in the tumorigenesis of second primary solid tumours.
Stomach, colon and rectum are potentially interesting sites in
this respect.
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Table VI Effects ofnumbers ofcycles ofchemotherapy on risk ofsubsequent
leukaemia as a second primary cancer for six chemotherapeutic agents, in
comparison with a baseline group receiving radiotherapy only
Agent Cycles Cases Control ORa (95% Clt)
Radiotherapy only - 2 8 1.00
Nitrogen mustard 1 2 1 14.77 (0.76,311.2)
2 + 1 2 5.21 (0.18,148.4)
Cyclophosphamide 1-2 2 11 0.59 (0.04,7.37)
3+ 8 13 2.34 (0.34,15.96)
Procarbazinec 1-2 2 11 0.69 (0.07,6.67)
3+ 7 13 1.85 (0.26,13.17)
Vinblastine 1-2 5 11 1.49 (0.20,10.74)
3+ 3 13 1.02 (0.14,7.28)
Vincristinec 1 2 1 26.23 (2.01,341.7)
2+ 8 3 1.50 (0.27,8.16)
Prednisolone 1-2 6 15 2.35 (0.19,28.76)
3+ 7 12 3.51 (0.22,53.87)
aOR = odds ratio. bCI = confidence interval.cTest fortrend,0.1 > P>0.05.
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